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Objective: Despite the increased cardiovascular morbidity and mortality risk of patients with peripheral arterial disease,
previous worldwide studies have documented undertreatment of cardiovascular risk factors in such patients.
Method: The ATTEST study was an observational cross-sectional epidemiologic study. Patients (n  8475) were selected
by 3020 general practitioners in France who were asked to include the first three patients with at least one site of proven
atherothrombotic disease (peripheral arterial disease of the lower limbs for two patients and coronary artery disease or
ischemic stroke for the third patient). We designed the ATTEST study to compare medical management of patients with
peripheral arterial disease, including pharmacologic treatment, cardiovascular tests, and physician’s assessment of future
cardiovascular and amputation risks, with patients with coronary artery disease or ischemic stroke.
Results: Only 13% of the patients with peripheral arterial disease (n  3811) received angiotensin converting enzyme
inhibitors, statins, and antiplatelet agents vs 30% of the patients with coronary artery disease or ischemic stroke (n 
4664). This undertreatment of the population with peripheral arterial disease was associated with a too-optimistic
physician’s assessment of future cardiovascular risk: only 27% of the general practitioners predicted a 5-year cardiovas-
cular risk >20%. Conversely, amputation risk prediction was greatly overestimated: only 44% of the practitioners
predicted a 5-year amputation risk <5%.
Conclusions: Patients with atherothrombotic disease recruited from primary care practices were not adequately tested and
treated, especially the patients with peripheral arterial disease. To improve the medical management of patients with
peripheral arterial disease, there is a need for epidemiologic and clinical education of physicians. ( J Vasc Surg 2006;44:
314-8.)Epidemiologic and natural history studies have deter-
mined that peripheral arterial disease (PAD) is highly prev-
alent and confers a high risk of fatal and nonfatal cardiovas-
cular and cerebrovascular events.1-4 The PAD Awareness,
Risk, and Treatment: New Resources for Survival (PART-
NERS) program has included 6979 patients aged 70
years or 50 to 69 years with a history of smoking or diabetes
mellitus in which PADwas detected by measurement of the
ankle-brachial index (ABI). The usual definition of ABI
0.9 was used to assess PAD in 1865 of these patients
(29%).1
Furthermore, in a longitudinal study, Criqui et al4
demonstrated that after a 5-year follow-up of 100 patients
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314with PAD, 16 cardiovascular deaths, 4 cerebrovascular
deaths, 3 other vascular deaths, and 7 nonvascular deaths
will occur (30% mortality at 5 years); during the same
period, two patients will undergo an amputation. Despite
this high prevalence of PAD in elderly patients and the
increased cardiovascular morbidity and mortality risk asso-
ciated with PAD, several studies have documented under-
treatment of cardiovascular risk factors in patients with
PAD.1,3,5,6
Again, in the PARTNERS program, participants with
PAD were treated less intensively with antihypertensives,
antiplatelet therapy, and cholesterol-lowering therapy than
those with coronary artery disease (CAD).1 Reasons for the
undertreatment of cardiovascular risk factors in patients
with PAD are not well understood. However, a national
survey study from the United States documented deficien-
cies in physician knowledge and attitudes regarding the
importance of treatment of atherosclerotic risk factors for
patients with PAD.5,6
The objectives of the ATTEST (prise en charge de
l’ArTériopaThie oblitErante des membreS inférieurs chez
les paTients en médecine générale) study were to compare
pharmacologic treatment (primary objective) and medical
management, including cardiovascular tests, and physi-
cian’s assessment of future cardiovascular and amputation
risks (secondary objectives) of patients with proven PAD
with patients with other vascular site(s) involved in athero-
thrombosis.
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Population. The design of the ATTEST study has
been reported elsewhere.7 Briefly, it was an observational,
cross-sectional epidemiologic study that took place in
France between April and November 2003. Patients were
selected by a geographically representative panel of 3020
general practitioners who agreed to participate in the study.
Each physician was asked to include the first three patients
identified from his or her practice to fulfill the inclusion
criteria. The inclusion criteria were patients (1) 18 years
old, (2) with at least one site of proven atherothrombotic
disease (PAD of the lower limbs for two patients and
proven CAD or ischemic stroke for the third patient), and
who were (3) willing to participate in the study and give
consent after receiving written and oral information. A total
of 8475 patients were included (all data completed) and
analyzed. The protocol was approved by the institutional
review committees Conseil National de l’Ordre des
Médecins, Comité Consultatif sur le Traitement de
l’Information en Matière de Recherche dans le domaine de
la Santé, Commission Nationale Informatique et Liberté.
Atherothrombotic diseases were defined using the In-
ternational Classification of Diseases (10th edition). PAD
disease was defined as typical symptoms of and/or severe
(70%) stenosis at arterial duplex or arteriography (99% of
patients had arterial duplex examinations), and/or a history
of surgical or percutaneous transluminal treatment for
lower limb arterial disease (excluding the renal and splanch-
nic circulation and abdominal aortic aneurysm). Coronary
heart disease was defined as any history of angina pectoris
(chest pain precipitated by exertion and relieved by rest or
nitrates) confirmed by coronary angiography, myocardial
infarction, typical sequelae on electrocardiography, coro-
nary percutaneous transluminal angioplasty, or coronary
artery bypass surgery or a combination. Cerebrovascular
disease was defined as a history of ischemic stroke con-
firmed by computed tomography or magnetic resonance
Table I. Cardiovascular risk factors of patients included in
disease
Parameters
Isolated PAD
n  3811
PA
Cardiovascular risk factors
Age (years) 66  12
Gender (% male) 80
Body mass index (kg/m2) 25.6  3.8
Hypertension (%) 58
Dyslipidemia (%) 62
Diabetes mellitus (%) 22
Current smoker (%) 44
SBP (mm Hg) 138  13
DBP (mm Hg) 79  8
LDL cholesterol (mmol/l) 3.36  0.78
PAD, Peripheral arterial disease;CAD, coronary artery disease;CVD, cerebro
low-density lipoprotein.
*Analysis of variance.imaging.A physician-completed inclusion questionnaire con-
tained the following data: gender, age, weight, height,
personal history of diabetes mellitus, dyslipidemia, or hy-
pertension, current and previous smoking habit, cardiovas-
cular tests previously performed, and current use of anti-
platelet, cardiovascular, lipid-lowering, and antidiabetic
drugs. These medical data were not obtained from a formal
testing protocol, and the ATTEST study was not planned
to add any tests to the management of the patients. Rather,
physicians were asked to give the most recent information
present in their medical files. Finally, the physicians were
asked to estimate future cardiovascular and amputation
risks, choosing for each of their 3 patients included for both
risks:5%, 5% to10%, 10% to20%, 20% to50%, and
50%.
Statistical analysis. The population was divided into
three groups: (1) patients with isolated PAD (n  3811),
(2) patients with PAD associated with atherosclerosis in at
least one other location, CAD or cerebrovascular disease (n
 2416), and (3) patients with CAD or cerebrovascular
disease, or both, but without PAD (n  2248). Quantita-
tive parameters were described by using means and stan-
dard deviations, and qualitative parameters by number and
percent. Qualitative parameter distributions within the
three groups were analyzed using the 2 test. Analysis of
variance (ANOVA) was used for quantitative parameter
comparisons among the three groups; no post hoc test was
performed. P .05 was considered significant. All analyses
were performed using SAS 8.1 software (SAS Institute,
Cary, NC).
RESULTS
Table I shows the cardiovascular risk factors of the
study population according to the site of atherothrombosis.
All ANOVA comparisons are statistically significant be-
cause of the large numbers. The most relevant differences
ATTEST study according to localization of vascular
d (CAD or CVD)
n  2416
CAD and/or CVD
(without PAD)
n  2248 P*
69  10 66  12 .001
83 76 .001
.3  3.9 26.6  3.9 .001
72 61 .001
73 70 .001
32 22 .001
32 23 .001
38  14 135  14 .001
79  9 78  8 .001
21  1.03 3.10  0.78 .001
lar disease; SBP, systolic blood pressure;DBP, diastolic blood pressure; LDL,the
D an
26
1
3.
vascushowed that patients with isolated PAD were more fre-
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poprotein cholesterol levels.
Characteristics of the patients concerning pharmaco-
logic treatment and medical management are given in
Table II. Patients with isolated PAD were less likely to be
treated with cardiovascular and lipid-lowering drugs. The
use of antiplatelet drugs, particularly aspirin, -blockers,
angiotensin-converting enzyme (ACE) inhibitors, calcium-
channel antagonists, diuretics, and statins, as well as the
combination of antiplatelet agents, ACE inhibitors, and
statins were all lower in the PAD group compared with the
other groups. In France, the right to full cost reimburse-
ment is provided for artery diseases, regardless of location.
However, practitioners tend to propose to their patients
such a full reimbursement less often in PAD than in the
other groups.
In addition, measurement of ABI was performed in
only a third of the patients with PAD. Cardiac tests were
also less likely to be performed in patients with PAD than in
the two other groups: electrocardiogram, 81% vs 94% and
93%; stress test, 40% vs 66% and 67%; myocardial scintigra-
phy, 6% vs 35% and 36%; and coronary angiography, 5% vs
60% and 67%.
Table III shows cardiovascular and amputation risk
predictions of the study population according to the site of
atherothrombosis. Patients with PAD were predicted to
Table II. Pharmacologic treatment and medical managem
localization of vascular disease
Parameters
Isolated PAD
n3811 (%)
Pharmacologic treatment
Aspirin 32
Clopidogrel/ticlopidine 66
No antiplatelet drug 8
-blockers 12
ACE inhibitors 23
Angiotensin II RA 17
Calcium-channel antagonist 25
Diuretic 23
Statin 53
Other hypocholesterolemic 10
Antidiabetic agent 18
Vasoactive agent 63
Antiplatelet  ACEI.  statin 13
Medical management
Medical cost full reimbursement 76
ABI measurement 34
Peripheral ADP 99
Cervical ADP 68
Abdominal ADP 59
Electrocardiogram 81
Stress test 40
Myocardial scintigraphy 6
Coronarography 5
PAD, peripheral arterial disease; CAD, coronary artery disease; CVD, cerebr
antagonist; ABI, ankle-brachial index; ADP, arterial duplex.
*Analysis of variancehave a more favorable risk profile than patients in the twoother groups (P  .001). Physician assessment of 5-year
cardiovascular death risk was 20% in 27% patients with
PAD vs 48% and 29% in the two other groups. Conversely,
amputation risk prediction was greatly overestimated: only
44% of the practitioners predicted a 5-year amputation risk
5% in the PAD group, which corresponds to published
data on its incidence of 2% risk at 5 years.4
DISCUSSION
The major findings of the ATTEST study are that (1)
this atherothrombotic population recruited from primary
care practices in France was not adequately tested and
treated as a whole, (2) the underuse of medical therapy was
especially true for patients with PAD, and (3) cardiovascu-
lar death risk was underestimated and amputation risk was
overestimated in patients with PAD.
In the ATTEST study, ABI was performed in only a
third of the patients with PAD. This result is not surprising,
because general practitioners in France rarely perform ABI.
However, several epidemiologic studies, such as the PART-
NERS program, have demonstrated that although more
than half of the patients with PAD have leg symptoms,
relatively few reported classic Rose claudication.1 In addi-
tion, PAD patients with atypical or no symptoms were
more likely to have their PAD diagnosis established only by
ABI measurement. Such data suggest that clinicians who
of patients included in the ATTEST study according to
PAD and
(CAD or CVD)
n2416 (%)
CAD and/or CVD
(without PAD)
n2248 (%) P*
39 54 .001
64 57 .001
8 6 .001
40 57 .001
46 41 .001
18 14 .001
42 31 .001
37 27 .001
71 74 .001
11 9 .003
29 18 .001
60 18 .001
31 30 .001
87 83 .001
31 9 .001
97 41 .001
71 61 .001
57 31 .001
94 93 .001
66 67 .001
35 36 .001
60 67 .001
lar disease; ACEI, angiotensin-converting enzyme inhibitor; RA, receptorent
ovascuuse a classic history of claudication alone to detect PAD (ie,
%, 20
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study) are likely to miss 85% to 90% of the patients with
PAD.1 Because atherosclerosis risk factor treatment is
clearly associated with better prognosis in patients with
PAD,3,8-10 we believe that late diagnosis (ie, absence of
ABI measurements) could be considered as the loss of a
chance for an improved outcome in these patients. In this
respect, some experts have proposed the creation of a
national PAD public awareness program.11
PAD confers a high cardiovascular risk,3 and the risks of
future cardiovascular events in patients with PAD are com-
parable with those in patients with CAD.8 In recent thera-
peutic trials that included heterogeneous populations at
increased cardiovascular risk, such as the Heart Protection
Study (HPS)9 and Heart Outcome Prevention Evaluation
(HOPE)10 trials, patients with PAD were at even greater
risk for cardiovascular events than patients with previous
myocardial infarction or patients with diabetes mellitus.
Despite these facts, in the ATTEST study, patients with
PAD were undertreated and cardiovascular tests were un-
derperformed.
Three classes of drugs—ACE inhibitors, statins, and
antiplatelet agents—have clearly demonstrated benefit in
patients with PAD with a high level of evidence.3,8-10 In the
present study, however, only 13% of the patients with PAD
received the combination of these drugs vs 30% of the
patients in the other groups. In contrast, a class of drugs
that was most frequently prescribed in the present study
was vasoactive agents, which have never been proven to
decrease cardiovascular morbid events. The same was true
concerning cardiovascular tests: only 40% of the patients
with PAD had had a stress test, although fatal myocardial
infarction is the leading cause of death in this population.
Previous reports worldwide are in accordance with
these findings.1,5,6,12 Part of the observed under-
management and undertreatment in the present population
Table III. General practitioner predictions of cardiovascu
study according to localization of vascular disease
5-year prediction*
Isolated PAD
n  3811 (%)
Cardiovascular death risk
5% 21
5% to 10% 25
10% to 20% 27
20% to 50% 20
50% 7
Amputation risk
5% 44
5% to 10% 27
10% to 20% 15
20% to 50% 10
50% 4
PAD, Peripheral arterial disease; CAD, coronary artery disease; CVD, cereb
*Different choices for risk prediction were, 5%, 5% to 10%, 10% to 20
†Analysis of variance.with PAD was probably related to a too-optimistic cardio-vascular risk prediction: only 27% of the practitioners pre-
dicted a 5-year cardiovascular risk 20%. On the contrary,
amputation risk prediction was greatly overestimated: only
44% of the practitioners predicted a 5-year amputation risk
5%.
Several limitations of the ATTEST study deserve men-
tion. First, because blood tests and cardiovascular tests were
not systematically performed, previous cardiovascular
events and prevalence of cardiovascular risk factors were
probably underestimated. Second, neither diagnostic nor
therapeutic recommendations were given to the investiga-
tors; priority was given to “real life” evaluation to be close
to everyday medical practice in its heterogeneity. This last
point is probably not true for antiplatelet agents, however.
In fact, the setup of the ATTEST study was performed in
association with a sensitization program concerning the
benefits of prescribing antiplatelet agents in patients with
atherothrombosis. So, the 13% of the patients receiving
ACE inhibitors, statins, and antiplatelet agents is probably
overestimated compared with the national prescription of
the combination of these drugs.
CONCLUSIONS
The increased cardiovascular morbidity and mortality
risk in patients with PAD could presumably be reduced by
appropriate lifestyle and pharmacologic interventions
within a primary care setting.3,8-10 Such interventions
should preferably be initiated by each patient’s general
practitioner, who has the best ability to establish the PAD
diagnosis and to maintain a long-term therapeutic relation-
ship with the patient. Furthermore, it is well known that
patients’ requests for treatment and attitudes about the
importance of treatment are major determinants of a phy-
sician’s behavior toward the use of preventive interven-
tions.13 Compared with patients with CAD without pe-
ripheral arterial disease, the high risk of cardiovascular
d amputation risks of patients included in the ATTEST
AD and
D or CVD)
2416 (%)
CAD and/or CVD
(without PAD)
n2248 (%) P†
.001
7 19
17 26
28 26
33 21
15 8
.001
38 88
28 7
18 2
11 1
5 2
ular disease.
% to 50% and 50%.lar an
P
(CA
n 
rovascevents associated with PAD and the benefits of cholesterol-
JOURNAL OF VASCULAR SURGERY
August 2006318 Blacher et allowering therapy were underestimated.6 Such findings may
help explain the low rates of cardiovascular risk factor
control previously reported in patients with PAD.6
Finally, because patients with PAD or CAD have the
same magnitude of cardiovascular risk,8-10 we believe that
improvement of PAD management needs epidemiologic
and medical education of the physicians, and measurement
of ABI should be systematic in the primary care in the
elderly or after the age of 50 in smokers or in patients with
diabetes.1
Members of the ATTEST Scientific Committee would
like to acknowledge the contribution of each general prac-
titioner.
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